Hexarelin Research Guide: Mechanism, Studies & Reconstitution Protocol

Hexarelin (also known as examorelin) is a synthetic hexapeptide growth hormone secretagogue (GHS) and one of the most potent GHS-R1a agonists characterized in research. Developed at the University of Milan in the 1990s as a tool compound for GH axis research, Hexarelin combines powerful GH-releasing activity with significant cardioprotective properties mediated through a separate, GH-independent receptor mechanism. Its dual biological profile, pituitary GH secretagogue and direct cardiac effector, has made it a subject of interest across endocrinology, cardiology, and metabolic research.

For research use only. Not intended for human or veterinary use.

Structure and Pharmacology

Hexarelin is a synthetic hexapeptide with the sequence His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2. The incorporation of D-2-methyltryptophan at position 2 confers increased GHS-R1a binding affinity and metabolic stability relative to earlier GHRPs, contributing to Hexarelin’s status as one of the most potent peptide GH secretagogues identified. Key pharmacological properties:

• Receptor: GHS-R1a (primary); CD36 scavenger receptor (cardioprotective effects)
• GH-releasing potency: Among the highest of any GHRP; produces larger GH pulses than GHRP-2, GHRP-6, or Ipamorelin at equivalent doses in most study models
• Half-life: Approximately 30–70 minutes
• Cortisol/ACTH elevation: Significant, more pronounced than GHRP-2
• Prolactin: Moderate elevation
• Desensitization: Exhibits tachyphylaxis (receptor desensitization) with repeated dosing more rapidly than other GHRPs, an important consideration in chronic research protocols

Mechanism of Action

GHS-R1a: Pituitary and Hypothalamic Actions

Like other GHRPs, Hexarelin activates GHS-R1a on pituitary somatotrophs via Gq protein coupling, triggering the IP3/DAG/calcium signaling cascade that drives GH exocytosis. Hexarelin also acts at hypothalamic GHS-R1a receptors to stimulate GHRH release and inhibit somatostatin secretion, amplifying GH output through a dual pituitary and hypothalamic mechanism. Its greater intrinsic efficacy at GHS-R1a compared to other GHRPs accounts for its superior GH-releasing potency in direct comparisons.

CD36 Receptor: GH-Independent Cardioprotection

A defining and clinically significant aspect of Hexarelin’s pharmacology is its activity at the CD36 scavenger receptor, a transmembrane glycoprotein expressed on cardiomyocytes, macrophages, platelets, and endothelial cells. Hexarelin binds CD36 independently of GHS-R1a, activating Src kinase and downstream survival pathways including PI3K/Akt and ERK1/2. This GH-independent cardioprotective mechanism was established by Bodart et al. (2002) and subsequently confirmed in multiple laboratories.

The discovery of CD36 as a Hexarelin receptor explains why Hexarelin’s cardioprotective effects are observed even in GH-deficient or hypophysectomized animals, where no GH secretion response to Hexarelin is possible, and provided mechanistic justification for research into Hexarelin in cardiac ischemia, heart failure, and fibrosis models independent of the GH axis.

Key Research Findings

GH-Releasing Potency

Ghigo et al. (1994) published foundational characterization of Hexarelin’s GH-releasing properties in healthy human subjects, demonstrating dose-dependent GH release substantially greater than that produced by GHRH alone at equivalent doses. The combination of Hexarelin + GHRH produced supra-additive GH peaks that exceeded those of any single agent, consistent with complementary GHRHr/GHS-R1a synergy observed across the GHRP class. These early studies established Hexarelin as the benchmark high-potency GHRP and contributed to its investigation as a GH deficiency diagnostic test agent.

Cardiac Ischemia and Cytoprotection

Bisi et al. (1999) and subsequent work demonstrated that Hexarelin exerts direct protective effects on the ischemic myocardium. In rodent ischemia-reperfusion injury models, Hexarelin administration reduced infarct size, preserved left ventricular function, and decreased cardiomyocyte apoptosis. These effects were observed in hypophysectomized animals, confirming GH-independence, and were attenuated by CD36 blockade, establishing the receptor pathway. The proposed intracellular mechanism involves Hexarelin-induced Akt phosphorylation and suppression of the mitochondrial apoptotic pathway (cytochrome c release, caspase-3 activation).

Heart Failure Research

Isgaard et al. (1997) investigated Hexarelin in a rat model of post-myocardial infarction heart failure, finding that chronic Hexarelin administration improved left ventricular function, reduced cardiac fibrosis, and attenuated ventricular remodeling. Notably, co-administration of GH with Hexarelin did not produce additive benefit beyond Hexarelin alone, further supporting the primacy of the GH-independent CD36 mechanism in cardiac outcomes. These findings generated interest in GHS-R1a/CD36 agonism as a research avenue for heart failure pharmacology.

Tachyphylaxis and Desensitization

A well-documented property of Hexarelin that distinguishes it from other GHRPs is its propensity for rapid desensitization. With repeated administration, GH responses to Hexarelin decline more rapidly than equivalent GHRP-6 or Ipamorelin protocols, a phenomenon attributed to both receptor downregulation at the pituitary level and increased somatostatin tone. Arvat et al. (1998) demonstrated that Hexarelin’s GH-releasing activity was substantially reduced after two weeks of daily administration in healthy subjects. This pharmacological property is an important variable to control for in chronic Hexarelin research protocols.

GH Deficiency Diagnosis

Hexarelin’s potent and reliable GH-releasing action has been studied as a pharmacological provocation test for GH deficiency. Popovic et al. (1995) evaluated the Hexarelin test versus the insulin tolerance test (ITT) in GH-deficient adults and found comparable sensitivity and specificity, with Hexarelin offering a safer alternative to hypoglycemia-inducing ITT. However, the combined GHRH + GHRP-2 test has generally shown superior discriminatory ability and has been more widely adopted as an ITT alternative in clinical practice.

Hexarelin in the GHRP Landscape

Hexarelin is the preferred GHRP for research specifically targeting CD36-mediated cardioprotective mechanisms, or when maximum single-dose GH pulse amplitude is the primary endpoint. Its tachyphylaxis profile makes it less suitable than Ipamorelin or GHRP-2 for long-duration chronic GH stimulation protocols.

Reconstitution Protocol

Hexarelin is supplied as a lyophilized white powder requiring reconstitution with bacteriostatic water prior to research use.

• Inject bacteriostatic water slowly along the inner wall of the vial, do not direct the stream onto the lyophilized powder
• Gently swirl until fully dissolved; solution should be clear and colorless
• Common research concentration: 2 mg/mL (add 1 mL BAC water to a 2 mg vial)
• Refrigerate reconstituted solution at 2–8°C; stable for approximately 4–6 weeks; protect from light
• Do not freeze reconstituted solution

References

• Ghigo, E., Arvat, E., Rizzi, G., Goffi, S., Grottoli, S., Mucci, M., … & Camanni, F. (1994). Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. Journal of Clinical Endocrinology and Metabolism, 78(3), 693–698.
• Bodart, V., Febbraio, M., Demers, A., McNicoll, N., Pohankova, P., Perreault, A., … & Bhatt, D. L. (2002). CD36 mediates the cardiovascular action of growth hormone-releasing peptides. Circulation Research, 90(8), 844–849.
• Bisi, G., Podio, V., Valetto, M. R., Broglio, F., Bertuccio, G., Del Rio, G., … & Ghigo, E. (1999). Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. Journal of Endocrinological Investigation, 22(4), 266–272.
• Isgaard, J., Törnell, J., Nilsson, A., Isaksson, O., & Lindahl, A. (1997). Effects of hexarelin on growth hormone and insulin-like growth factor-I in hypophysectomized rats. Growth Hormone and IGF Research, 7, 177–181.
• Arvat, E., Di Vito, L., Maccario, M., Broglio, F., Boghen, M. F., Deghenghi, R., … & Ghigo, E. (1998). Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. European Journal of Endocrinology, 139(4), 449.

All content on this site is intended strictly for in vitro research and laboratory use. Products sold by Exceed Enhancement are not approved by the FDA and are not intended for human consumption, therapeutic use, or veterinary application.

Research-Grade Products Available

• TB-500 10mg →
• 30ml Bacteriostatic Sodium Chloride →
• 3ml Bacteriostatic water →
• 30ml Hospira Bacteriostatic water →